LBRX — LB Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $736.66m
- $441.44m
Annual cashflow statement for LB Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG |
| Status: | Final | Final | Final |
| Net Income/Starting Line | -6.28 | -63.1 | -25.2 |
| Depreciation | |||
| Non-Cash Items | -4.51 | 6.65 | 3.33 |
| Unusual Items | |||
| Other Non-Cash Items | |||
| Changes in Working Capital | -1.31 | 3.31 | -13.7 |
| Change in Prepaid Expenses | |||
| Change in Accrued Expenses | |||
| Change in Payable / Accrued Expenses | |||
| Cash from Operating Activities | -12.1 | -53.1 | -35.2 |
| Capital Expenditures | -0.025 | -0.769 | -0.052 |
| Purchase of Fixed Assets | |||
| Other Investing Cash Flow Items | -28 | 24 | -39.8 |
| Sale/Maturity of Investment | |||
| Purchase of Investments | |||
| Cash from Investing Activities | -28 | 23.2 | -39.9 |
| Financing Cash Flow Items | -0.089 | -1.71 | -25.4 |
| Other Financing Cash Flow | |||
| Net Issuance / Retirement of Stock | |||
| Net Issuance / Retirement of Debt | |||
| Cash from Financing Activities | 33.7 | 38.3 | 303 |
| Beginning Cash Balance | |||
| Ending Cash Balance | |||
| Net Change in Cash | -6.42 | 8.5 | 227 |